A new oral weight loss pill shows results similar to Ozempic and Wegovy injections in the treatment of obesity.

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The maker of Ozempic and Wegovy found fake 1-milligram injections were being distributed through unauthorized sellers.

Currently, only liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) are approved for weight loss, though some other GLP-1 drugs may be prescribed off-label. Keep in mind that ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...

Wegovy was approved to tackle weight loss on the NHS in 2023, while Ozempic and Rybelus are available on the health service as treatments for type 2 diabetes. The study examined the health records ...

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling ...

The Centres for Medicare and Medicaid Services on Friday said that it did not move forward with a proposal put forward by the ...

Pfizer to discontinue danuglipron weight-loss drug, but has other obesity treatments ... which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro ...